Analysis of Blood Samples from Patients who Responded to the BriLife® Vaccine During Phase 2 Trial Suggests that the Same Level of Response was Seen Against the Delta Variant as Against the Original “Wild-Type” Virus
Data Suggest that the BriLife Vaccine May Be Capable of Evolving to Counter Delta and Other Variants of Concern
NRx to Commence Phase 2b/3 Registration Trial of BriLife® After Upcoming Phase 2 Data Safety Monitoring Board Review
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.